Evidence map›Paper›PMID 38548342›Full record

ArticleBMJ global health2024

Estimation of country-specific tuberculosis resistance antibiograms using pathogen genomics and machine learning.

Avika Dixit, Luca Freschi, Roger Vargas, Matthias I Gröschel, Maria Nakhoul, Sabira Tahseen, S M Masud Alam, S M Mostofa Kamal, Alena Skrahina, Ramon P Basilio and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 6 countries.

Avika DixitDivision of Infectious Diseases, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.
Luca FreschiDepartment of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.
Roger VargasDepartment of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.
Matthias I GröschelDepartment of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.
Maria NakhoulInformatics and Analytics Department, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID http://orcid.org/0000-0003-1354-4552
Sabira TahseenNational Tuberculosis Control Programme, Islamabad, Pakistan.
S M Masud AlamMinistry of Health and Family Welfare, Kolkata, West Bengal, India.
S M Mostofa KamalNational Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh.
Alena SkrahinaRepublican Scientific and Practical Center for Pulmonology and Tuberculosis, Minsk, Belarus.
Ramon P BasilioResearch Institute for Tropical Medicine, Muntinlupa City, Philippines.
Dodge R LimResearch Institute for Tropical Medicine, Muntinlupa City, Philippines.
Nazir IsmailClinical Microbiology and Infectious Diseases, University of the Witwatersrand Johannesburg Faculty of Health Sciences, Johannesburg, South Africa.ORCID http://orcid.org/0000-0001-7696-3776
Maha R FarhatDepartment of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA Maha_Farhat@hms.harvard.edu.
Harvard University · USResearch Institute for Tropical Medicine · PHBoston Children's Hospital · USDana-Farber Cancer Institute · USMinistry of Health and Family Welfare · INNational Institute of Cardiovascular Diseases · BDRepublican Scientific and Practical Centre of Pulmonology and Tuberculosis · BYUniversity of the Witwatersrand · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlobal tuberculosis (TB) drug resistance (DR) surveillance focuses on rifampicin. We examined the potential of public and surveillance

methodsWe curated and quality-controlled

results

conclusionsThis is the first attempt at global

Indexed as

Antitubercular AgentsTuberculosis, Multidrug-ResistantEthionamideGenomicsHumansIsoniazidMachine LearningMicrobial Sensitivity TestsRifampinAntitubercular AgentsEthionamideIsoniazidRifampinTuberculosis

Identifiers

PMID38548342
PMCPMC10982777
OpenAlexW4393282224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.